Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier

被引:3
作者
Birk Poller
Jürgen Drewe
Stephan Krähenbühl
Jörg Huwyler
Heike Gutmann
机构
[1] University Hospital of Basel,Department of Clinical Pharmacology and Toxicology
[2] University of Applied Sciences Northwestern Switzerland,Department of Pharmaceutical Technology
[3] Novartis Institute for Biomedical Research,Novartis Pharma AG
[4] TS,undefined
[5] DMPK,undefined
来源
Cellular and Molecular Neurobiology | 2010年 / 30卷
关键词
Blood–brain barrier; P-Glycoprotein; BCRP; Interleukin-6; Interleukin-1 beta; Tumor necrosis factor-alpha;
D O I
暂无
中图分类号
学科分类号
摘要
Brain capillary endothelial cells form the blood–brain barrier (BBB), a highly selective permeability membrane between the blood and the brain. Besides tight junctions that prevent small hydrophilic compounds from passive diffusion into the brain tissue, the endothelial cells express different families of drug efflux transport proteins that limit the amount of substances penetrating the brain. Two prominent efflux transporters are the breast cancer resistance protein and P-glycoprotein (P-gp). During inflammatory reactions, which can be associated with an altered BBB, pro-inflammatory cytokines are present in the systemic circulation. We, therefore, investigated the effect of the pro-inflammatory cytokines interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) on the expression and activity of BCRP and P-gp in the human hCMEC/D3 cell line. BCRP mRNA levels were significantly reduced by IL-1β, IL-6 and TNF-α. The strongest BCRP suppression at the protein level was observed after IL-1β treatment. IL-1β, IL-6 and TNF-α also significantly reduced the BCRP activity as assessed by mitoxantrone uptake experiments. P-gp mRNA levels were slightly reduced by IL-6, but significantly increased after TNF-α treatment. TNF-α also increased protein expression of P-gp but the uptake of the P-gp substrate rhodamine 123 was not affected by any of the cytokines. This in vitro study indicates that expression levels and activity of BCRP, and P-gp at the BBB may be altered by acute inflammation, possibly affecting the penetration of their substrates into the brain.
引用
收藏
页码:63 / 70
页数:7
相关论文
共 176 条
[1]  
Bauer B(2007)Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood–brain barrier Mol Pharmacol 71 667-675
[2]  
Hartz AM(2005)The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients Cancer Res 65 2577-2582
[3]  
Miller DS(2004)Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood–brain barrier Cancer Res 64 3296-3301
[4]  
Breedveld P(2002)Localisation of breast cancer resistance protein in microvessel endothelium of human brain NeuroReport 13 2059-2063
[5]  
Pluim D(1989)Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood–brain barrier sites Proc Natl Acad Sci USA 86 695-698
[6]  
Cipriani G(2008)ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier J Neurochem 107 1518-1528
[7]  
Wielinga P(1996)The influence of cytokines on the integrity of the blood–brain barrier in vitro J Neuroimmunol 64 37-43
[8]  
van Tellingen O(1997)The blood–brain barrier in neuroinflammatory diseases Pharmacol Rev 49 143-155
[9]  
Schinkel AH(2007)Blood–brain barrier pathology in Alzheimer’s and Parkinson’s disease: implications for drug therapy Cell Transplant 16 285-299
[10]  
Schellens JH(2002)A new multidrug resistance protein at the blood–brain barrier Biochem Biophys Res Commun 293 1273-1278